Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Immune Design Corp (IMDZ)

NASDAQ
Currency in USD
Disclaimer
5.85
0.00(0.00%)
Closed
IMDZ Scorecard
Fair Value
Unlock Value
Day's Range
5.845.85
52 wk Range
0.005.85
Prev. Close
5.85
Open
5.84
Day's Range
5.84-5.85
52 wk Range
0-0
Volume
0
Average Vol. (3m)
607,193
1-Year Change
0%
Shares Outstanding
48,365,248
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about IMDZ?
Vote to see community's results!
or

Immune Design Corp Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, focuses on cancer with in vivo approaches to enable the body’s immune system to fight disease. The company develops products based on its ZVex and GLAAS discovery platforms. Its lead product candidate is G100, a monotherapy and combination therapy that is in Phase II clinical trials for treating patients with follicular non-Hodgkin lymphoma. The company has collaboration and license agreements with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck Sharp & Dohme Corp. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck & Co., Inc.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.